Influenza Antiviral Treatment and Length of Stay.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
10 2021
Historique:
accepted: 21 06 2021
pubmed: 3 9 2021
medline: 18 12 2021
entrez: 2 9 2021
Statut: ppublish

Résumé

Antiviral treatment is recommended for hospitalized patients with suspected and confirmed influenza, but evidence is limited among children. We evaluated the effect of antiviral treatment on hospital length of stay (LOS) among children hospitalized with influenza. We included children <18 years hospitalized with laboratory-confirmed influenza in the US Influenza Hospitalization Surveillance Network. We collected data for 2 cohorts: 1 with underlying medical conditions not admitted to the ICU ( Compared with those not receiving antiviral agents, LOS was shorter for those treated ≤2 days after illness onset in both the medical conditions (adjusted hazard ratio: 1.37, Early antiviral treatment was associated with significantly shorter hospitalizations in children with laboratory-confirmed influenza and high-risk medical conditions or children treated in the ICU. These results support Centers for Disease Control and Prevention recommendations for prompt empiric antiviral treatment in hospitalized patients with suspected or confirmed influenza.

Sections du résumé

BACKGROUND
Antiviral treatment is recommended for hospitalized patients with suspected and confirmed influenza, but evidence is limited among children. We evaluated the effect of antiviral treatment on hospital length of stay (LOS) among children hospitalized with influenza.
METHODS
We included children <18 years hospitalized with laboratory-confirmed influenza in the US Influenza Hospitalization Surveillance Network. We collected data for 2 cohorts: 1 with underlying medical conditions not admitted to the ICU (
RESULTS
Compared with those not receiving antiviral agents, LOS was shorter for those treated ≤2 days after illness onset in both the medical conditions (adjusted hazard ratio: 1.37,
CONCLUSIONS
Early antiviral treatment was associated with significantly shorter hospitalizations in children with laboratory-confirmed influenza and high-risk medical conditions or children treated in the ICU. These results support Centers for Disease Control and Prevention recommendations for prompt empiric antiviral treatment in hospitalized patients with suspected or confirmed influenza.

Identifiants

pubmed: 34470815
pii: peds.2021-050417
doi: 10.1542/peds.2021-050417
pii:
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCHM CDC HHS
ID : U38 HM000414
Pays : United States
Organisme : OSTLTS CDC HHS
ID : U38 OT000143
Pays : United States

Informations de copyright

Copyright © 2021 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

POTENTIAL CONFLICT OF INTEREST: Evan J. Anderson has received personal fees from AbbVie, Pfizer, Sanofi Pasteur, and Medscape for consulting, and his institution receives funds to conduct clinical research unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GlaxoSmithKline, Merck, Novavax, Sanofi Pasteur, Janssen, and Micron. He also serves on a safety monitoring board for Kentucky BioProcessing, Inc. and Sanofi Pasteur. have indicated that they have no financial relationships relevant to this article to disclose. The remaining authors have indicated that they have no financial relationships relevant to this article to disclose.

Auteurs

Angela P Campbell (AP)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia app4@cdc.gov.

Jerome I Tokars (JI)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.

Sue Reynolds (S)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.

Shikha Garg (S)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.

Pam Daily Kirley (PD)

California Emerging Infections Program, Oakland, California.

Lisa Miller (L)

Communicable Disease Branch, Colorado Department of Public Health and Environment, Denver, Colorado.

Kimberly Yousey-Hindes (K)

Connecticut Emerging Infections Program, Yale School of Public Health, Yale University, New Haven, Connecticut.

Evan J Anderson (EJ)

Pediatrics and Medicine, Emory University School of Medicine and the Atlanta Veterans Affairs Medical Center, Atlanta, Georgia.

Oluwakemi Oni (O)

Iowa Department of Public Health, Des Moines, Iowa.

Maya Monroe (M)

Emerging Infections Program, Maryland Department of Health, Baltimore, Maryland.

Sue Kim (S)

Communicable Disease Division, Michigan Department of Health and Human Services, Lansing, Michigan.

Ruth Lynfield (R)

Minnesota Department of Health, St Paul, Minnesota.

Chad Smelser (C)

New Mexico Department of Health, Santa Fe, New Mexico.

Alison T Muse (AT)

New York State Department of Health, Albany, New York.

Christina Felsen (C)

University of Rochester Medical Center, Rochester, New York.

Laurie M Billing (LM)

Bureau of Infectious Diseases, Ohio Department of Health, Columbus, Ohio.

Ann Thomas (A)

Oregon Public Health Division, Portland, Oregon.

Elizabeth Mermel (E)

Rhode Island Department of Health, Providence, Rhode Island.

Mary Lou Lindegren (ML)

Vanderbilt University School of Medicine, Nashville, Tennessee.

William Schaffner (W)

Vanderbilt University School of Medicine, Nashville, Tennessee.

Andrea Price (A)

Bureau of Epidemiology, Salt Lake County Health Department, Salt Lake City, Utah.

Alicia M Fry (AM)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH